Analysis of circulating forms of proBNP and NT-proBNP in patients with severe heart failure

Clinical Chemistry

Volumn 54, Issue 5, 2008, Pages 858-865

  Hammerer Lercher, Angelika ^a   Halfinger, Bernhard ^a   Sarg, Bettina ^a   Mair, Johannes ^b   Puschendorf, Bernd ^a   Griesmacher, Andrea ^a   Guzman, Norberto A ^a   Lindner, Herbert H ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; IMMUNOGLOBULIN F(AB) FRAGMENT;

AFFINITY CHROMATOGRAPHY; ARTICLE; CONTROLLED STUDY; DEGLYCOSYLATION; DISEASE SEVERITY; ELECTROSPRAY MASS SPECTROMETRY; HEART FAILURE; HUMAN; TANDEM MASS SPECTROMETRY; WESTERN BLOTTING;

CHROMATOGRAPHY, AFFINITY; CHROMATOGRAPHY, LIQUID; GLYCOSYLATION; HEART FAILURE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; SEVERITY OF ILLNESS INDEX; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY;

OVIS ARIES;

EID: 43449109489     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2007.090266     Document Type: Article

References (31)

1. Nieminen MS, Bohm M, Cowie MR, Drexler H, Filippatos GS, Jondeau G, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: The Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:384-416.
2. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:1115-40.
3. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005;112:e154-235.
4. Galvani M, Ferrini D, Ottani F. Natriuretic peptides for risk stratification of patients with acute coronary syndromes. Eur J Heart Fail 2004;6:327-33.
5. Bjorklund E, Jernberg T, Johanson P, Venge P, Dellborg M, Wallentin L, Lindahl B. Admission NT-proBNP and its interaction with admission troponin T and ST-segment resolution for early risk stratification in ST-elevation myocardial infarction. Heart 2006;92:735-40.
6. Melzi d'Eril G, Tagnochetti T, Nauti A, Klersy C, Papalia A, Vadacca G, et al. Biological variation of N-terminal pro-brain natriuretic peptide in healthy individuals. Clin Chem 2003;49:1554-5.
7. Wu AH, Smith A, Apple FS. Optimum blood collection intervals for B-type natriuretic peptide testing in patients with heart failure. Am J Cardiol 2004;93:1562-3.
8. Bruins S, Fokkema MR, Römer JW, Dejongste MJ, van der Dijs FP, van den Ouweland JM, Muskiet FA. High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. Clin Chem 2004;50:2052-8.
9. Hammerer-Lercher A, Puschendorf B, Mair J. Btype natriuretic peptides as powerful markers in cardiac diseases - analytical and clinical aspects. J Lab Med 2006;30:165-84.
10. Mair J, Hammerer-Lercher A, Puschendorf B. The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Clin Chem Lab Med 2001;39:571-88.
11. Shimizu H, Masuta K, Aono K, Asada H, Sasakura K, Tamaki M, et al. Molecular forms of human brain natriuretic peptide in plasma. Clin Chim Acta 2002;316:129-35.
12. Shimizu H, Masuta K, Asada H, Sugita K, Sairenji T. Characterization of molecular forms of probrain natriuretic peptide in human plasma. Clin Chim Acta 2003;334:233-9.
13. Ala-Kopsala M, Magga J, Peuhkurinen K, Leipala J, Ruskoaho H, Leppaluoto J, Vuolteenaho O. Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments of A- and B-type natriuretic peptides. Clin Chem 2004;50:1576-88.
14. Hawkridge AM, Heublein DM, Bergen HR 3rd, Cataliotti A, Burnett JC Jr, Muddiman DC. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci U S A 2005;102:17442-7.
15. Yandle TG, Richards AM, Gilbert A, Fisher S, Holmes S, Espiner EA. Assay of brain natriuretic peptide (BNP) in human plasma: evidence for high molecular weight BNP as a major plasma component in heart failure. J Clin Endocrinol Metab 1993;76:832-8.
16. Schellenberger U, O'Rear J, Guzzetta A, Jue RA, Protter AA, Pollitt NS. The precursor to B-type natriuretic peptide is an O-linked glycoprotein. Arch Biochem Biophys 2006;451:160-6.
17. Yeo KT, Wu AH, Apple FS, Kroll MH, Christenson RH, Lewandrowski KB, et al. Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta 2003;338:107-15.
18. Karl J, Borgya A, Gallusser A, Huber E, Krueger K, Rollinger W, Schenk J. Development of a novel, N-terminal-proBNP (NT-proBNP) assay with a low detection limit. Scand J Clin Lab Invest Suppl 1999;230:177-81.
19. Collinson PO, Barnes SC, Gaze DC, Galasko G, Lahiri A, Senior R. Analytical performance of the N terminal pro B type natriuretic peptide (NTproBNP) assay on the Elecsys 1010 and 2010 analysers. Eur J Heart Fail 2004;6:365-8.
20. Guzman NA. Immunoaffinity capillary electrophoresis applications of clinical and pharmaceutical relevance. Anal Bioanal Chem 2004;378:37-9.
21. Guzman NA, Phillips TM. Immunoaffinity CE for proteomics studies. Anal Chem 2005;77:61A-7A.
22. Sarg B, Helliger W, Talasz H, Foerg B, Lindner HH. Histone H1 phosphorylation occurs site-specifically during interphase and mitosis: identification of a novel phosphorylation site on histone H1. J Biol Chem 2006;281:6573-80.
23. Togashi K, Kameya T, Ando K, Marumo F, Kawakami M. Brain natriuretic peptides in human plasma, spinal cord and cerebrospinal fluid. Clin Chim Acta 1991;201:193-200.
24. Tateyama H, Hino J, Minamino N, Kangawa K, Minamino T, Sakai K, et al. Concentrations and molecular forms of human brain natriuretic peptide in plasma. Biochem Biophys Res Commun 1992;185:760-7.
25. Hunt PJ, Yandle TG, Nicholls MG, Richards AM, Espiner EA. The amino-terminal portion of probrain natriuretic peptide (Pro-BNP) circulates in human plasma. Biochem Biophys Res Commun 1995;214:1175-83.
26. Hunt PJ, Espiner EA, Nicholls MG, Richards AM, Yandle TG. The role of the circulation in processing pro-brain natriuretic peptide (proBNP) to amino-terminal BNP and BNP-32. Peptides 1997;18:1475-81.
27. Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN, Espiner EA. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol (Oxf) 1997;47:287-96.
28. Seferian KR, Tamm NN, Semenov AG, Mukharyamova KS, Tolstaya AA, Koshkina EV, et al. The brain natriuretic peptide (BNP) precursor is the major immunoreactive form of BNP in patients with heart failure. Clin Chem 2007;53:866-73.
29. Giuliani I, Rieunier F, Larue C, Delagneau JF, Granier C, Pau B, et al. Assay for measurement of intact B-type natriuretic peptide prohormone in blood. Clin Chem 2006;52:1054-61.
30. Crimmins DL. Human N-terminal proBNP is a monomer. Clin Chem 2005;51:1035-8.
31. Seidler T, Pemberton C, Yandle T, Espiner E, Nicholls G, Richards M. The amino terminal regions of proBNP and proANP oligomerise through leucine zipper-like coiled-coil motifs. Biochem Biophys Res Commun 1999;255:495-501.